N
CDMO

Natixis’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Natixis’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-26,000
Closed -$530K – 1419
2022
Q1 		$530K Buy
26,000
+12,000
+86% +$244K ﹤0.01% 977
2021
Q4 		$409K Buy
+14,000
New +$401K ﹤0.01% 1068

Other funds holding CDMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

Natixis's CDMO Position: Q2 2022 in Review

Natixis sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q2 2022, closing a stake of 26,000 shares — an estimated $530K sold.

Natixis first reported a position in CDMO in Q4 2021 and held it in 2 quarters. The position peaked at $530K in Q1 2022. 187 funds tracked by Wall St. Rank hold CDMO as of Q2 2022.

  • Natixis reported no remaining Avid Bioservices, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Natixis sold 26,000 Avid Bioservices, Inc. Common Stock shares in Q2 2022, an estimated $530K.
  • Natixis first reported a position in Avid Bioservices, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Natixis's Avid Bioservices, Inc. Common Stock position peaked at $530K in Q1 2022.
  • 187 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q2 2022.

Based on Natixis's 13F filing for Q2 2022, filed 12 Aug 2022.